Tesamorelin and Sermorelin are both synthetic growth hormone-releasing hormone (GHRH) analogues. Sermorelin is often used as a treatment for growth hormone deficiency in both children and adults. Sermorelin works by mimicking the action of the natural hormone, growth hormone-releasing hormone (GHRH), to increase the production of growth hormone in the body. This can have various benefits, including promoting growth in children, increasing muscle mass, reducing body fat, improving sleep, and enhancing overall well-being. Sermorelin is typically administered to individuals with growth hormone deficiencies or certain medical conditions. Tesamorelin is used primarily to treat excess abdominal fat accumulation in people living with HIV/AIDS who have developed lipodystrophy. Lipodystrophy is a condition characterized by abnormal fat distribution in the body. Tesamorelin works by stimulating the pituitary gland to release growth hormone, which can help reduce visceral fat (fat stored in the abdominal area) in these individuals. It is administered through daily injections. Both peptides are known for their ability to bring about changes in body composition, and both have been linked to improvements in heart health and cognitive function in mouse models. Despite their similarities, however, there are unique differences between these peptides. Understanding the subtleties that arise between these two very similar peptides is helping researchers to better understand physiologic pathways and develop better, more advanced therapeutics.